The estimated Net Worth of Mark Bodmer is at least 1.5 百万$ dollars as of 7 November 2023. Mark Bodmer owns over 6,625 units of Evelo Biosciences Inc stock worth over 650$ and over the last 6 years he sold EVLO stock worth over 12,002$. In addition, he makes 1,487,500$ as Chief Scientific Officer、 President of Research and Development at Evelo Biosciences Inc.
Mark has made over 6 trades of the Evelo Biosciences Inc stock since 2023, according to the Form 4 filled with the SEC. Most recently he exercised 6,625 units of EVLO stock worth 149$ on 7 November 2023.
The largest trade he's ever made was exercising 132,500 units of Evelo Biosciences Inc stock on 7 May 2023 worth over 2,981$. On average, Mark trades about 19,141 units every 14 days since 2018. As of 7 November 2023 he still owns at least 28,895 units of Evelo Biosciences Inc stock.
You can see the complete history of Mark Bodmer stock trades at the bottom of the page.
DR. Mark Bodmer Ph.D. serves as Chief Scientific Officer, President of Research and Development of the Company.D., is the Chief Scientific Officer, President of Research and Development of the Company. He joined Evelo as President of R&D and CSO in April 2016. He has extensive experience in both biotech and big pharma as a drug R&D leader and CEO. Mark was one of the early pioneers of therapeutic humanized antibodies at Celltech, which included starting and leading the project that resulted in the first ever study in man of an anti-TNF antibody. As well as anti-TNF, his time at Celltech led to a number of marketed medicines in inflammatory diseases and cancer, including reslizumab and gemtuzumab. After Celltech, Mark spent 10 years as CEO of a number of venture-backed biotech companies in the UK. He was the founding CEO of genomics company, Hexagen, which was acquired by Incyte Pharmaceuticals and Mark served as SVP of Research for Incyte. Between 2007 and joining Evelo Mark held R&D leadership positions at GSK and UCB. These included heading discovery and early development in a variety of therapeutic areas including metabolic and cardiovascular, immuno-inflammation and neurology from which several medicines are currently in clinical development. Mark has a BA and PhD in Genetics from Cambridge University.
As the Chief Scientific Officer、 President of Research and Development of Evelo Biosciences Inc, the total compensation of Mark Bodmer at Evelo Biosciences Inc is 1,487,500$. There are 1 executives at Evelo Biosciences Inc getting paid more, with Balkrishan Gill having the highest compensation of 2,802,000$.
Mark Bodmer is 63, he's been the Chief Scientific Officer、 President of Research and Development of Evelo Biosciences Inc since 2016. There are 1 older and 14 younger executives at Evelo Biosciences Inc. The oldest executive at Evelo Biosciences Inc is Stephen J. Carriere, 66, who is the VP & Chief Accounting Officer.
Mark's mailing address filed with the SEC is C/O EVELO BIOSCIENCES, INC., ONE KENDALL SQUARE, 600/700, SUITE 7-201, CAMBRIDGE, MA, 02139.
Over the last 7 years, insiders at Evelo Biosciences Inc have traded over 41,656$ worth of Evelo Biosciences Inc stock and bought 38,579,214 units worth 81,620,674$ . The most active insiders traders include Ventures Fund Iv General Pa...、Noubar Afeyan、Ventures Fund Iv General Pa.... On average, Evelo Biosciences Inc executives and independent directors trade stock every 45 days with the average trade being worth of 19,676$. The most recent stock trade was executed by Mark Bodmer on 7 November 2023, trading 6,625 units of EVLO stock currently worth 149$.
evelo biosciences is dedicated to improving the lives of patients globally through the development of a new modality of medicines – monoclonal microbials. monoclonal microbials are orally delivered medicines that modulate systemic immunology and biology through direct interactions with human cells in the gut. these new medicines are broadly applicable across many diseases – including autoimmune, immunoinflammatory, metabolic, neurological, neuroinflammatory diseases and cancer. monoclonal microbials have the potential to fundamentally change traditional models of drug discovery and development. by finding and selecting naturally occurring monoclonal microbials with defined therapeutic effects, evelo can improve the speed, cost and success of drug discovery and development. evelo’s platform enables pharmacological intervention at all stages of disease with naturally occurring, safe and effective monoclonal microbials. evelo biosciences was conceived and created within venturelabs®, flag
Evelo Biosciences Inc executives and other stock owners filed with the SEC include: